SpyGlass Pharma, Inc.(SGP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SGP Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for SpyGlass Pharma, Inc. (SGP), a Healthcare sector company. SGP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), SpyGlass Pharma, Inc. reports net income of $-19.9M, free cash flow of $-16.8M. Top institutional holders of SGP by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., NEA Management Company, Sands Capital Ventures, based on the most recent SEC filings. SGP trades on the Nasdaq exchange and files with the SEC under CIK 1778922. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SpyGlass Pharma, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-19.9M
Free Cash Flow
Q2 2026
$-16.8M
ROIC
Q2 2026
-37.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-36.7% YoYOperating Income
-53.2% YoYEPS (Diluted)
-10.2% YoYTotal Assets
+396.9% YoYOp. Cash Flow
-48.5% YoYFree Cash Flow
-39.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Income | $-39.9M -36.7% | $-29.2M | — |
| Operating Income | $-41.4M -53.2% | $-27.1M | — |
| EPS (Diluted) | $-17.98 -10.2% | $-16.31 | — |
| Total Assets | $115.9M +396.9% | $23.3M | — |
| Operating Cash Flow | $-32.7M -48.5% | $-22.0M | — |
| Free Cash Flow | $-33.5M -39.4% | $-24.0M | — |
Get alerted when SGP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SpyGlass Pharma, Inc. including:
Top Institutional Holders of SGP
RA CAPITAL MANAGEMENT, L.P.
$178.6M8,021,117 shNEA Management Company, LLC
$164.6M7,392,301 shSands Capital Ventures, LLC
$55.7M2,500,012 shSamsara BioCapital, LLC
$47.0M2,109,953 shBlackRock, Inc.
$15.8M711,712 shPRICE T ROWE ASSOCIATES INC /MD/
$15.0M674,143 shVestal Point Capital, LP
$14.9M670,000 shJPMORGAN CHASE & CO
$13.6M629,739 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$12.2M550,000 shMILLENNIUM MANAGEMENT LLC
$11.3M507,257 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $178.6M | 8,021,117 |
| NEA Management Company, LLC | $164.6M | 7,392,301 |
| Sands Capital Ventures, LLC | $55.7M | 2,500,012 |
| Samsara BioCapital, LLC | $47.0M | 2,109,953 |
| BlackRock, Inc. | $15.8M | 711,712 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $15.0M | 674,143 |
| Vestal Point Capital, LP | $14.9M | 670,000 |
| JPMORGAN CHASE & CO | $13.6M | 629,739 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $12.2M | 550,000 |
| MILLENNIUM MANAGEMENT LLC | $11.3M | 507,257 |
More Healthcare Companies
View all Healthcare →Put SGP on your watchlist
Track score changes the day SpyGlass Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SGP a good stock to buy?
13F Pro's AI-powered analysis of SpyGlass Pharma, Inc. (SGP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SGP are available on the SGP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SGP is classified as a small company.
Which hedge funds own SGP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SGP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SpyGlass Pharma, Inc.'s investment landscape.